https://www.empiri.co/press-releases/empirico-announces-strategic-collaboration-to-harness-human-genetics-for-the-discovery-and-development-of-novel-antisense-oligonucleotide-therapeutics/ 2023-11-22T18:03:56+00:00 monthly 0.6 https://www.empiri.co/press-releases/abcellera-and-empirico-announce-strategic-multi-target-antibody-discovery-collaboration/ 2023-11-22T18:02:37+00:00 monthly 0.6 https://www.empiri.co/press-releases/abcellera-and-empirico-expand-strategic-multi-target-antibody-discovery-collaboration/ 2023-11-22T18:02:53+00:00 monthly 0.6 https://www.empiri.co/press-releases/gsk-and-empirico-enter-license-agreement-for-clinical-stage-first-in-class-oligonucleotide-candidate-to-treat-respiratory-diseases/ 2025-10-27T19:15:59+00:00 monthly 0.6